EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

The value of serum levels of IL-6, TNF-alpha, and erythropoietin in metastatic malignant melanoma: serum IL-6 level is a valuable prognostic factor at least as serum LDH in advanced melanoma



The value of serum levels of IL-6, TNF-alpha, and erythropoietin in metastatic malignant melanoma: serum IL-6 level is a valuable prognostic factor at least as serum LDH in advanced melanoma



Medical Oncology 22(3): 241-246



In order to study the relation to the metastatic profile and survival, we evaluated the association between pretreatment serum levels of IL-6, TNF-alpha, and erythropoietin (EPO) and metastatic distribution and survival in 16 patients with metastatic malignant melanoma. IL-6 and TNF-alpha immunoassay (R&D Systems, Inc. Minneapolis, USA) employs the quantitative sandwich enzyme immunoassay technique. The Quantikine IVD EPO ELISA (R&D Systems, Inc.) is based on the double-antibody sandwich method. The baseline serum IL-6 and EPO levels were significantly higher in patients with metastatic malignant melanoma than in the control group (p = 0.009 and p = 0.033, respectively). Serum IL-6 levels were higher in patients with weight loss (p = 0.02), who were anemic (p = 0.026), with elevated serum LDH levels (p = 0.028), and who were chemotherapy nonresponding (p = 0.016). The relationship of serum IL-6 concentration to the tumor burden was not determined. Only serum EPO level was influenced by hemoglobin status (p = 0.001). No difference was shown among these three parameters. Elevated serum IL-6 concentration (p = 0.002) was found to be an adverse prognostic factor in patients with poor performance status, weight loss, low serum hemoglobin, elevated serum LDH, and unresponsive to chemotherapy. On the other hand, both serum TNF-alpha and EPO levels were of no prognostic value. Serum levels of IL-6 were found to be prognostic factors as valuable as serum LDH levels in patients with metastatic malignant melanoma. Their prognostic value should be further evaluated in a larger patient population.

(PDF emailed within 0-6 h: $19.90)

Accession: 050762372

Download citation: RISBibTeXText

PMID: 16110135

DOI: 10.1385/MO:22:3:241



Related references

The value of serum levels of IL-6, TNF-alpha, and erythropoietin in metastatic malignant melanoma. Medical Oncology (Totowa) 22(3): 241-246, 2005

Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer 106(5): 1130-1139, 2006

Elevated Serum Level of YLK-40 Is an Independent Prognostic Factor for Poor Survival in Patients with Metastatic Melanoma. Yearbook of Dermatology and Dermatologic Surgery 2007: 358-359, 2007

Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study. Melanoma Research 15(3): 199-204, 2005

Serum S-100 B a prognostic factor in malignant melanoma. Clinical Chemistry 47(S6): A133-A134, June, 2001

Evaluation of serum YKL-40 as a prognostic marker for overall survival in patients with metastatic malignant melanoma. Journal of Clinical Oncology 23(16_suppl): 7520-7520, 2016

Serum levels of cytokines and soluble cytokine receptors in patients with metastatic renal cell carcinoma or malignant melanoma receiving IL-2/interferon-alpha combination therapy. Acta Oncologica 34(5): 599-603, 1995

Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Research 5(1): 67-68, 1995

Elevated serum levels of S100 and survival in metastatic malignant melanoma. British Journal Of Cancer. 75(9): 1373-1376, 1997

Elevated serum levels of S100 and survival in metastatic malignant melanoma. British Journal of Cancer 75(9): 1373-1376, 1997

Melanoma Inhibiting Activity A new prognostic serum marker in patients with malignant melanoma. Clinical Chemistry & Laboratory Medicine 37(SPEC SUPPL ): S226, June, 1999

S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 56(4): 338-344, 1999

Melanoma inhibitory activity Changes of serum level after development of metastatic disease in patients with choroidal melanoma. IOVS 41(4): S567, March 15, 2000

Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients. Melanoma Research 9(2): 155-161, 1999

Increased serum level of thymidine kinase 1 correlates with metastatic site in patients with malignant melanoma. Tumour Biology 34(2): 643-648, 2013